Management of Uncomplicated Recurrent Urinary Tract Infections

European Urology Supplements - Tập 15 - Trang 95-101 - 2016
Winfried Vahlensieck1, Tamara Perepanova2, Truls E. Bjerklund Johansen3, Peter Tenke4, Kurt G. Naber5, Florian M.E. Wagenlehner6
1Department of Urology, Hospital for Rehabilitation Kurpark-Klinik, Bad Nauheim, Germany
2Department of UTI and Clinical Pharmacology, N. Lopatkin Scientific Research Institute of Urology and Interventional Radiology, branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, Russia
3Urology Department, Oslo University Hospital, Oslo, Norway
4Department of Urology, Jahn Ference Del-Pesti Korhaz, Budapest, Hungary
5Department of Urology, Technical University of Munich, Munich, Germany
6Clinic for Urology, Pediatric Urology and Andrology, Justus-Liebig University of Giessen, Giessen, Germany

Tài liệu tham khảo

Stamey, 1987, Recurrent urinary tract infections in female patients: an overview of management and treatment, Rev Infect Dis, 9, S195, 10.1093/clinids/9.Supplement_2.S195

Vahlensieck, 2015, Therapy strategies in recurrent urinary tract infections [in German], Nieren- und Hochdruckkrkh, 44, 299, 10.5414/NHX01723

O’Grady, 1966, Kinetics of urinary tract infection. II. The bladder, Br J Urol, 38, 156, 10.1111/j.1464-410X.1966.tb09694.x

Kunin, 1997

Hooton, 2001, Recurrent urinary tract infection in women, Int J Antimicrob Agents, 17, 259, 10.1016/S0924-8579(00)00350-2

Dudar, 2009, 12-month comparative study of administration of Canephron® N in the treatment of patients with the urinary tract infection, Health of Man Ukraine, 3, 85

Fuenfstueck, 1997, Prevention of reinfection by L-methionine in patients with recurrent urinary tract infection [in German], Med Klin (Munich), 92, 574

Riedasch, 1986, Immunotherapy in women with recurrent urinary tract infections [in German], Therapiewoche, 6, 896

Raz, 2010, Urinary tract infections in postmenopausal women, 225

Schaeffer, 1999, Efficacy and safety of self-start therapy in women with recurrent urinary tract infections, J Urol, 161, 207, 10.1016/S0022-5347(01)62099-8

L’Agence française de sécurité sanitaire des produits de santé (afssaps). Nitrofurantoïne et risqué de survenue d’effets indésirables hépatiques et pulmonaires lors de traitements prolongés. Pharmacovigilance 2011. Infectiologie Web site. http://www.infectiologie.com/site/medias/_documents/consensus/lp-110311-%20nitrofurantoine.pdf